IFIH1 and dermatomyositis: Recent studies focusing on anti-melanoma differentiation-associated gene 5 (MDA-5) antibody-positive dermatomyositis have underscored the urgent need for aggressive therapeutic approaches, including steroid pulse therapy and early initiation of immunosuppressive therapy [17–19].